Leap Therapeutics Shares Rise Premarket on Encouraging Study Data

By Colin Kellaher

Shares of Leap Therapeutics Inc. rose more than 10% in premarket trading Wednesday after the biotechnology company reported positive data from a Phase 2a study of DKN-01, its most advanced clinical candidate, in combination with BeiGene Ltd.'s tislelizumab.

The Cambridge, Mass., company said the combination showed encouraging clinical activity in both first- and second-line advanced gastric or gastroesophageal junction cancer patients.

Leap is conducting the study as part of an exclusive option and license agreement with BeiGene for the development of DKN-01 in Asia (excluding Japan), Australia and New Zealand.

Leap shares, which closed Tuesday at $2.72, were recently up 11.4% to $3.03 in premarket trading.

Write to Colin Kellaher at [e-mail]

(END) Dow Jones Newswires

01-19-22 0702ET